Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
158
0.780
 Why?
Anus Neoplasms
1
2018
24
0.600
 Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1003
0.520
 Why?
Bone Marrow Neoplasms
1
2015
13
0.510
 Why?
Embolism
1
2015
20
0.510
 Why?
Gene Regulatory Networks
1
2016
107
0.500
 Why?
Carcinoma, Squamous Cell
1
2018
325
0.490
 Why?
Tumor Lysis Syndrome
1
2014
5
0.480
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
54
0.460
 Why?
Neoplasm Recurrence, Local
1
2018
634
0.450
 Why?
Pyrazoles
1
2014
111
0.440
 Why?
Pyrimidines
1
2014
193
0.430
 Why?
Angiogenesis Inhibitors
2
2006
182
0.420
 Why?
Clinical Trials as Topic
5
2019
465
0.420
 Why?
Salvage Therapy
1
2013
136
0.410
 Why?
Biliary Tract Diseases
1
2012
12
0.410
 Why?
Actinomycosis
1
2012
10
0.410
 Why?
Bile Duct Neoplasms
1
2012
28
0.410
 Why?
Stomach Neoplasms
1
2015
189
0.400
 Why?
Gene Expression Profiling
1
2016
1029
0.380
 Why?
Prognosis
6
2019
1979
0.380
 Why?
Benzenesulfonates
2
2011
10
0.370
 Why?
Middle Aged
12
2020
12460
0.360
 Why?
Carcinoma, Hepatocellular
1
2013
196
0.360
 Why?
Stroke
1
2015
485
0.350
 Why?
Pyridines
2
2011
132
0.330
 Why?
Liver Neoplasms
1
2013
331
0.330
 Why?
Colorectal Neoplasms
2
2003
256
0.320
 Why?
Aged, 80 and over
6
2018
3180
0.290
 Why?
Heparin
1
2007
91
0.280
 Why?
Drug Industry
1
2007
38
0.280
 Why?
Thrombocytopenia
1
2007
84
0.280
 Why?
Communication Barriers
1
2007
31
0.280
 Why?
Hypertensive Encephalopathy
1
2006
3
0.270
 Why?
raf Kinases
1
2006
4
0.270
 Why?
Thiazolidinediones
1
2007
82
0.270
 Why?
Aged
9
2020
9590
0.250
 Why?
Anticoagulants
1
2007
254
0.240
 Why?
Thrombosis
1
2007
249
0.240
 Why?
Skin
1
2007
417
0.230
 Why?
Adult
9
2020
13568
0.230
 Why?
Enzyme Inhibitors
1
2006
378
0.230
 Why?
Female
11
2020
26981
0.230
 Why?
Survival Rate
2
2018
915
0.220
 Why?
Prostatic Neoplasms
1
2007
394
0.210
 Why?
Humans
16
2020
50389
0.210
 Why?
Follow-Up Studies
3
2019
2219
0.210
 Why?
Camptothecin
1
2002
16
0.200
 Why?
Male
10
2020
25718
0.200
 Why?
Antineoplastic Agents, Phytogenic
1
2002
67
0.190
 Why?
Lung Neoplasms
1
2007
600
0.190
 Why?
Oximes
1
2020
13
0.180
 Why?
Diabetes Mellitus, Type 2
1
2007
516
0.180
 Why?
Pyrimidinones
1
2020
19
0.180
 Why?
Pyridones
1
2020
35
0.180
 Why?
Thalidomide
1
2002
374
0.170
 Why?
Imidazoles
1
2020
128
0.170
 Why?
Cholangiocarcinoma
2
2011
26
0.160
 Why?
Protein Kinase Inhibitors
1
2020
205
0.160
 Why?
Survival Analysis
3
2020
671
0.150
 Why?
Antineoplastic Agents
2
2019
1178
0.140
 Why?
Melanoma
1
2020
281
0.140
 Why?
Neoplasm Staging
2
2013
750
0.130
 Why?
Combined Modality Therapy
1
2018
641
0.130
 Why?
Severity of Illness Index
1
2019
963
0.130
 Why?
Antibodies, Monoclonal
1
2019
462
0.120
 Why?
Skin Neoplasms
1
2020
487
0.120
 Why?
Gene Amplification
1
2015
57
0.120
 Why?
Adenine
1
2014
31
0.120
 Why?
Polycomb Repressive Complex 2
1
2015
46
0.120
 Why?
Genes, myc
1
2015
40
0.120
 Why?
Retrospective Studies
3
2018
6223
0.120
 Why?
United States
3
2019
4913
0.110
 Why?
Piperidines
1
2014
96
0.110
 Why?
Gene Deletion
1
2015
267
0.110
 Why?
Registries
3
2007
539
0.110
 Why?
Treatment Outcome
4
2020
5230
0.110
 Why?
Quinazolines
1
2013
32
0.110
 Why?
Leukemia, Myeloid, Acute
1
2015
180
0.110
 Why?
Actinomyces
1
2012
10
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2016
830
0.100
 Why?
Endoscopy, Gastrointestinal
1
2012
76
0.100
 Why?
Comorbidity
2
2019
617
0.100
 Why?
Gallbladder Neoplasms
1
2011
7
0.100
 Why?
Antibodies, Monoclonal, Humanized
1
2013
224
0.090
 Why?
Phenylurea Compounds
2
2011
15
0.090
 Why?
Niacinamide
2
2011
23
0.090
 Why?
Incidence
2
2019
1017
0.090
 Why?
Neoplasms
1
2019
1237
0.080
 Why?
Necrosis
1
2007
175
0.070
 Why?
Drugs, Investigational
1
2007
14
0.070
 Why?
Causality
1
2007
47
0.070
 Why?
Hospitals, University
1
2007
78
0.070
 Why?
Confidence Intervals
1
2007
154
0.070
 Why?
Age Distribution
1
2007
170
0.070
 Why?
Probability
1
2007
165
0.070
 Why?
Neoplasm Metastasis
2
2011
235
0.070
 Why?
Tomography, X-Ray Computed
1
2012
1160
0.070
 Why?
United States Food and Drug Administration
1
2007
91
0.070
 Why?
Anti-Bacterial Agents
1
2012
745
0.070
 Why?
Medical Oncology
1
2007
96
0.070
 Why?
Syndrome
1
2006
239
0.060
 Why?
Patient Selection
1
2007
257
0.060
 Why?
Publication Bias
1
2005
11
0.060
 Why?
Editorial Policies
1
2005
11
0.060
 Why?
Periodicals as Topic
1
2005
57
0.060
 Why?
Dose-Response Relationship, Drug
1
2007
1356
0.050
 Why?
Risk Assessment
1
2007
1258
0.050
 Why?
MAP Kinase Kinase Kinases
1
2020
19
0.040
 Why?
Socioeconomic Factors
1
2003
590
0.040
 Why?
Proto-Oncogene Proteins B-raf
1
2020
78
0.040
 Why?
Mutation, Missense
1
2020
104
0.040
 Why?
Drug Administration Schedule
1
2020
369
0.040
 Why?
Trisaccharides
1
2019
1
0.040
 Why?
Premedication
1
2019
17
0.040
 Why?
Administration, Oral
1
2020
432
0.040
 Why?
Magnetic Resonance Imaging
1
2006
1534
0.040
 Why?
Infusions, Intravenous
1
2019
213
0.040
 Why?
Antibodies
1
2019
151
0.040
 Why?
Health Services Accessibility
1
2003
420
0.040
 Why?
Disease Management
1
2019
175
0.040
 Why?
Arkansas
1
2003
1991
0.030
 Why?
Adolescent
1
2007
6475
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2015
256
0.030
 Why?
Polymorphism, Single Nucleotide
1
2015
482
0.020
 Why?
Young Adult
1
2020
4064
0.020
 Why?
Disease-Free Survival
1
2011
450
0.020
 Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (127) concept(s)
_
Co-Authors Expand Description
See all (1) people
_
Similar People Expand Description
See all (33) people
_
Same Department Expand Description
Search Department